Rapid detox procedures are marketed as a fast, sedated way to get through withdrawal — but they carry real risks and aren’t endorsed as standard practice by ASAM or other major addiction medicine bodies.
What’s actually being sold: These procedures typically involve administering an opioid antagonist (like naltrexone) while the person is under sedation or general anesthesia, intended to compress withdrawal into a period of unconsciousness rather than days of conscious discomfort.
Why this isn’t the shortcut it’s marketed as:
- Anesthesia itself carries real medical risk, on top of whatever risk withdrawal already carries
- There have been documented deaths associated with these procedures
- It does not improve long-term outcomes compared to standard approaches, according to the available evidence, despite the significantly higher cost
- It does nothing to address the underlying opioid use disorder — someone still needs ongoing treatment afterward, which the procedure itself doesn’t provide
The cost problem: These procedures are often marketed at $5,000–$10,000 or more, frequently paid out of pocket, for a process that doesn’t outperform much less expensive, evidence-based approaches. cost estimator tool
What ASAM and similar bodies actually recommend instead: Standard medically supervised withdrawal management, ideally paired with a direct transition to medication for opioid use disorder rather than detox alone. [“detox is not treatment” article]
Medically reviewed by [pending]. Sources: ASAM National Practice Guideline, case reports in emergency medicine literature on rapid detox complications.